SAN DIEGO--(BUSINESS WIRE)--Artes Medical, Inc. (Nasdaq: ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced 5-year safety and efficacy data for ArteFill®, the Company’s non-resorbable FDA-approved injectable dermal filler. The Company intends to submit the data from its 5-year follow-up study to the FDA for review in order to enhance the product labeling for ArteFill. The data will also be presented at the 65th annual meeting of the American Academy of Dermatology in Washington, D.C. on February 2, 2007 by Dr. Mark G. Rubin, Assistant Clinical Professor of Dermatology, University of California, San Diego, Division of Dermatology. The clinical data represents the culmination of a significant follow-up study of 145 patients who were treated with ArteFill in the Company’s U.S. clinical trial.
